Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer

International Journal of Oncology

Volumn 10, Issue 1, 1997, Pages 177-182

  Pappot, Helle ^a   Pfeiffer, Per ^b   Grøndahl Hansen, Jan ^a,c   Skov, Birgit Guldhammer ^d  

^a FINSEN LABORATORY   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Lung cancer; Plasminogen activation; uPA

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TISSUE LEVEL;

EID: 0031028834     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.1.177     Document Type: Article

References (46)

1. Fischer A: Mechanism of the proteolytic activity of malignant tissue cells. Nature 157: 442, 1946.
2. Goldhaber P, Cornman I and Ormsbee RA: Experimental alteration of the ability of tumor cells to lyse plasma clots in vitro. Proc Soc Exp Biol Med 66: 590-595, 1947.
3. Blasi F, Vassalli JD and Danø K: Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 104: 801-804, 1987.
4. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
5. Pollänen J, Stephens R and Vaheri A: Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 57: 273-382, 1991.
6. Günzler WA, Steffens GJ, Ötting F, Kim SMA, Frankus E and Flohé L: The primary structure of high molecular mass urokinase from human urine. Hoppe Seyler Z Physiol Chem 363: 1155-1165, 1982.
7. + RNA. Proc Natl Acad Sci USA 81: 4727-4731, 1984.
8. Edlund T, Ny T, Rånby M, Heden LO, Palm G, Holmgren E and Josephson S: Isolation of cDNA sequences coding for a part of human tissue plasminogen activator. Proc Natl Acad Sci USA 80: 349-352, 1983.
9. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV and Collen D: Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301: 214-221, 1983.
10. Petersen LC, Lund LR, Nielsen LS, Danø K and Skriver L: One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 263: 11189-11195, 1988.
11. Ellis V, Pyke C, Eriksen J, Solberg H and Danø K: The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 667: 13-31, 1992.
12. Ellis V and Danø K: Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemostasis 17: 194-200, 1991.
13. Murphy G, Ward R, Gavrilovic J and Atkinson S: Physiological mechanisms for metalloproteinase activation. In: Matrix Metalloproteinases and Inhibitors. Birkedal-Hansen H, Werb Z, Welgus H and van Wart H (eds). Gustav Fischer Verlag, Stuttgart, pp245-255, 1992.
14. Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L and Danø K: Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 261: 7644-7651, 1986.
15. Pyke C, Kristensen P, Ralfkiær E, Grøndahl-Hansen J, Eriksen J, Blasi F and Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067, 1991.
16. Pyke C, Græm N, Ralfkiær W, Rønne E, Høyer-Hansen G, Brünner N and Danø K: The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915, 1993.
17. Pyke C, Ralfkiær E, Rønne E, Høyer-Hansen G, Kirkeby L and Danø K: Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24: 131-138, 1994.
18. Pyke C: Histological investigation of human metastasizing tumors for components of the plasminogen activation system. Ph.D. Thesis, University of Copenhagen, 1994.
19. Danø K, Grøndahl-Hansen J, Eriksen J, Schnack Nielsen B, Rømer J and Pyke C: The receptor for urokinase plasminogen activator. Stromal cell involvement in extracellular proteolysis during cancer invasion. In: Proteolysis and Protein Turnover. Barrett AJ and Bond J (eds). Portland Press, London, pp239-245, 1993.
20. Andreasen PA, Georg B, Lund LR, Riccio A and Stacey SN: Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1-19, 1990.
21. Kristensen P, Pyke C, Lund LR, Andreasen PA and Danø K: Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 93: 559-566, 1990.
22. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M and Pyke C: The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8: 189-203, 1994.
23. Pyke C, Kristensen P, Ralfkiær E, Eriksen J and Danø K: The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 51: 4067-4071, 1991.
24. Sappino AP, Belin D, Huarte J, Hirshelscholz S, Saurat JH and Vassalli JD: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073-1079, 1991.
25. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829, 1990.
26. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
27. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
28. Jänicke F, Schmitt M and Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostasis 17: 303-312, 1991.
29. Ganesh S, Sier CFM, Griffioen G, Vloedgraven IJM, de Boer A, Welvaart K, van de Velde CJH, et al: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071, 1994.
30. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP and Sheahan K: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584, 1994.
31. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y and Simiyoshi A: The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 151: 16-20, 1994.
32. Nekarda H, Siewert JR, Schmitt M and Ulm K: Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 343: 117, 1994.
33. Pedersen H, Grøndahl-Hansen J, Francis D, Østerlind K, Hansen HH, Danø K and Brünner N: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-122, 1994.
34. Ganesh S, Sier CFM, Heerding MM, Griffioen G, Lamers CBHW and Verspaget HW: Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402, 1994.
35. Grøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N and Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995.
36. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, Danø K and Grøndahl-Hansen J: Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675, 1994.
37. Heidtmann HH, Hofmann M, Jacob E, Erbil C and Havemann K: Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. Cancer Res 49: 6960-6965, 1989.
38. Schwartz-Albeiz R, Heidtmann HH, Wolf D, Schirrmacher V and Moldenhauer G: Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase. Br J Cancer 65: 51-57, 1992.
39. Gris JC, Schved JF, Marty-Double C, Mauboussin JM and Balmes P: Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest 104: 8-13, 1993.
40. Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM and Stump D: Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 65: 481-485, 1990.
41. Pappot H and Brünner N: The plasminogen activation system and its role in lung cancer. A review. Lung Cancer 12: 1-12, 1995.
42. World Health Organization. The World Health Organization histological typing of lung tumors. WHO, Genova, 1981.
43. Camiolo SM, Suita MR and Madeja JM: Improved medium for extraction of plasminogen activator from tissue. Prep Biochem 12: 297-305, 1982.
44. Rosenquist C, Thorpe SM, Danø K and Grøndahl-Hansen J: Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat 28: 223-230, 1993.
45. Rønne E, Høyer-Hansen G, Brünner N, Pedersen H, Rank F, Danø K and Grøndahl-Hansen J: Urokinase-type receptor in breast cancer tissue extracts: enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 33: 199-207, 1995.
46. Danø K, Oronsky A and Gjedde S: Proteases from cultured malignant cells. FEBS Lett 47: 113-125, 1978.